Kadia TM, Js C, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Montalban-Bravo G, Issa G, Naqvi K, Short N, Dinardo C, Bhalla K, Jabbour E, Takahashi K, Sasaki K, Kornblau S, Malla R, Pierce S, Estrov Z, Andreeff M , Garcia-Manero G, Ravandi F, and Kantarjian H
Start with your goal
HCV-Induced oxidative stress: battlefield-winning strategy
Intermediate values were observed for liraglutide (11 days, IQR 257), tirzepatide (19 days, IQR 369), lixisenatide (20 days, IQR 5116), and semaglutide (27 days, IQR 577) (Table S6)
These bypass the healthcare system entirely
placebo-controlled insomnia data exists but results are inconsistent